Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clesacostat
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Clesacostat is a small molecule, liver-directed acetyl-CoA carboxylase (ACC) inhibitor developed by Pfizer for the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). It acts by inhibiting ACC, a key enzyme in lipid metabolism, thereby reducing hepatic steatosis. Clesacostat has been studied both as monotherapy and in combination with ervogastat (a diacylglycerol O-acyltransferase 2 inhibitor), with the combination showing reduced liver fat and favorable safety profiles in clinical trials. The drug is currently in Phase II clinical development for NASH with fibrosis[1][2][3][4][5][7].
- Other names
- 1370448-25-1
02
Targets
ACC (Acetyl-CoA Carboxylase 1)
Beyond the preview
Go deeper on clesacostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clesacostat.